LUCENTIS - Ranibizumab InjectionLines gained. Lives changed.
For US Healthcare Professionals Only

About Ranibizumab|Attributes

LUCENTIS was specifically designed for intravitreal administration for wet AMD1


LUCENTIS molecule LUCENTIS molecule *
  • • As an antibody fragment, LUCENTIS is designed to be a small molecule with a molecular weight of
    48 kD1
  • • LUCENTIS has a short half-life with rapid intrinsic systemic elimination (half-life ~2 hours)1,2
  • • Absence of the Fc portion on the antibody prevents binding to Fc receptors on the cells2,3

LUCENTIS was manufactured and packaged for intravitreal use1

  • LUCENTIS was formulated using the USP 789 guidelines to meet the specifications required by the FDA for intravitreal therapies1,4
  • LUCENTIS is designed to form minimal aggregates (<1.5%)—this is due in part to removal of certain amino acids during the affinity maturation process5

Affinity maturation increases the binding affinity of LUCENTIS
(0.15 nM)3

  • LUCENTIS binds to multiple VEGF-A isoforms and cleavage products6
  • LUCENTIS has been engineered to specifically bind with high affinity to VEGF-A1,2
Tools & Resources

Get information on conferences, events, and how to order LUCENTIS and other materials for your patients.

LUCENTIS Resources 
LUCENTIS Access Solutions™

Helps resolve access and reimbursement issues for patients. Our specialists help patients gain access to LUCENTIS while supporting your practice throughout the reimbursement process.

Visit LUCENTIS Access Solutions 
LUCENTIS Direct

With LUCENTIS Direct, you can order LUCENTIS straight from Genentech. It’s friendly service and fast, overnight delivery.

Visit the Web site 
Call Us
Get more information on LUCENTIS at:
1.866.LUCENTIS
(1.866.582.3684)
Monday-Friday
9 AM-8 PM ET


INDICATION

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.

Although there was a low rate (<4%) of arterial thromboembolic events (ATEs) observed in LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of inhibitors of VEGF.

Serious adverse events related to the injection procedure occurring in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. Other serious ocular events occurring in <2% of patients included intraocular inflammation with or without hypersensitivity and increased IOP.

In clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, and vitreous floaters. Most common nonocular side effects included nasopharyngitis, headache, respiratory and urinary tract infections.

LUCENTIS is for prescription use only.

Individual results with LUCENTIS may vary.

Please see LUCENTIS full Prescribing Information